Navigation Links
Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer
Date:2/18/2008

BOSTON--One of the shortcomings of a therapy that uses millions of identical antibodies to boost the immune system's attack on cancer cells is that many patients whose tumors recede in response to the treatment also experience serious inflammatory problems, such as severe diarrhea and rashes. In a new study, a team led by Dana-Farber Cancer Institute researchers shows that giving periodic infusions of such "monoclonal" antibodies to patients who have received a widely used cancer vaccine unleashes a strong immune response to tumors, with less-harsh side effects.

The study, to be published online by the Proceedings of the National Academy of Sciences on the week of Feb. 18, reflects efforts to untangle the benefits of monoclonal antibody therapy from its drawbacks, which result from a too-aggressive immune system assault on normal, healthy tissue. Besides demonstrating the potential usefulness of a vaccine-and-antibody approach, the new study suggests a way of refining treatment strategies even further, based on the biological events that antibody treatment sets in motion.

"We now have a better understanding of how the treatment works -- by increasing the ratio of tumor-killing to immune system-suppressing cells," says the study's lead author, Stephen Hodi, MD, of Dana-Farber. "This suggests techniques for further focusing the immune system to attack the cancer with less 'fallout' for normal tissue."

The study focused on a molecular socket, or receptor, on the surface of the immune system's CD4+ T cells, which guide an attack on infected or cancerous cells. The receptor, known as CTLA-4 (for cytotoxic T lymphocyte-associated antigen), functions as a kind of shut-off valve for CD4+ T cells: When the receptor is stimulated, it causes the T cells to become inactive, quieting the immune response. Blocking CTLA-4 with a monoclonal antibody -- a protein uniquely fit for the job -- offers a way to keep the immune response at full force.

Studies and clinical experience have shown that CTLA-4-targeting monoclonal antibodies do increase the immune system's tumor-destroying activities in some patients. But many of these patients also develop serious inflammatory conditions, raising the possibility that the therapeutic and harmful effects of the treatment are linked.

The current study involved a cancer vaccine made from patients' own tumor cells. The vaccine is created by removing tumor cells from the body, irradiating them so they stop growing, and inserting a gene that causes them to produce a protein called GVAX. When the cells are then re-infused into patients, GVAX acts like a siren to the immune system, prompting a more energetic attack on cancer cells throughout the body.

Unfortunately, these results are rarely lasting. Most patients treated with the vaccine eventually die as their disease resumes its progress.

For that reason, researchers have begun studying whether combining GVAX vaccines with monoclonal antibody therapy could lengthen remissions, since blocking CTLA-4 could bolster the immune response spurred by the vaccine. And there was reason to think the combination could tamp down the inflammatory problems associated with antibody therapy alone.

"Using a vaccine to provoke a stronger immune response to cancer may enable us to use lower levels of CTLA-4 blockers, which could reduce the severity of their side effects," Hodi explains.

In an earlier study, he and his colleagues demonstrated that a single infusion of anti-CTLA-4 antibodies caused extensive tumor destruction in all five metastatic melanoma and ovarian cancer patients who had previously been immunized with a GVAX vaccine.

The new study, a joint effort of Dana-Farber's melanoma program and Cancer Vaccine Center, tested the combination in a larger number of participants. Eleven melanoma patients were infused with a CTLA-4-blocking antibody (Ipilumimab (R)) one to four months after receiving GVAX, and every two to three months thereafter, as needed.

In contrast to previous, more intensive antibody doses, none of the patients had severe side effects, although they all developed mild, low-level inflammatory conditions (usually a rash that went away in a few days). Moreover, in eight of the participants, tumors throughout the body either receded or became stable. The three other patients experienced less dramatic improvements that became apparent after several months of therapy.

Similarly encouraging results were obtained in nine patients with advanced ovarian cancer, although two of them did develop severe inflammatory problems. Although large die-offs of tumor tissue were less common than in the melanoma group, some of the ovarian cancer patients did experience such results.

To understand what was happening at a basic cellular level, researchers studied tumor samples from six patients following antibody treatment. They found that tumor death was greatest in samples with high ratios of CD8+ T cells -- the foot soldiers of immune system attack -- to FoxP3+ regulatory T cells, which can reduce the immune response.

"Our results suggest that combination therapies of GVAX vaccine and CTLA-4-blocking antibodies could be enhanced by agents that target regulatory T cells such as FoxP3+," remarks Hodi, who is also an assistant professor of medicine at Harvard Medical School. "Future work will focus in that direction."


'/>"/>

Contact: Bill Schaller
william_schaller@dfci.harvard.edu
617-632-5357
Dana-Farber Cancer Institute
Source:Eurekalert

Related medicine news :

1. Scientists move towards stem cell therapy trials to mend shattered bones
2. Chemotherapy After Breast Cancer Surgery Effective for Older Women, Too
3. Viral Therapy Slows Pediatric Tumors in Mice
4. HIV persists in the gut despite long-term HIV therapy
5. GPS for the Prostate: System Keeps Radiation Therapy on Target
6. Study reveals why certain ovarian cancers develop resistance to platinum-based chemotherapy
7. Stop & Shop Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products
8. Giant Food Alerts Customers to Voluntary Recall of Chattem Icy Hot Heat Therapy Products
9. Seattle Cancer Care Alliance and Northwest Hospital Sign Letter of Intent to Develop Proton Therapy Center for Cancer Treatment
10. Study suggests new therapy for lung disease patients
11. Radiation Therapy Services, Inc. Shareholders Approve Merger Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Sharon Kleyne is ... product of her research center at Bio-Logic Aqua Research® Water Life Science®, has ... greatest number of sufferers of blindness. “We think that Nature’s Tears® EyeMist® will ...
(Date:7/21/2017)... ... July 21, 2017 , ... How physicians and ... the rise, say researchers presenting their work at the American Orthopaedic Society ... combination of evaluating the patterns of change in concussion symptom presentation, diagnostic tools ...
(Date:7/20/2017)... (PRWEB) , ... July 20, ... ... provider of enterprise-grade IT operations analytics and application performance monitoring (APM) solutions, ... world’s largest healthcare services providers. , According to Peter Ohrenberger, sales director ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... Team Type ... access to medicine for everyone affected by diabetes, is teaming up with a Microsoft ... global event kicks off on July 24th. , “Team Type 1’s mission overlaps ...
(Date:7/20/2017)... ... July 20, 2017 , ... Using ... Aug. 9, 2017 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/mdqualitydata          ... boosting quality. , It’s known as the “CY2016 Annual FDA Medical Device Quality ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... July 10, 2017 Locus Biosciences Inc. today ... support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for ... leading Chinese Internet services provider, and joined by the ... infectious disease product programs targeting antibiotic resistant infections and ... Founded by Dr. Rodolphe Barrangou and Dr. ...
(Date:7/5/2017)... BOTHELL, Wash. , July 5, 2017   ... a leading developer, manufacturer and marketer of proprietary clinical ... cryopreservation freeze media ("BioLife"), today announced that ... ("WAVI") its debt holder and largest shareholder, to modify ... Pursuant to the modification, WAVI agreed to ...
Breaking Medicine Technology: